Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Correction with GLP-1 in Cardiovascular Diseases in Kazakhstan
NCT07303556Active, not recruiting
- Sponsor
- Nazarbayev University
- Start
- Dec 2024
- Primary completion
- Jul 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of tirzepatide in heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Nazarbayev University. Primary endpoints: N-terminal pro-b-type natriuretic peptide at 24 weeks, Glycated hemoglobin at 40 weeks and 3 more. Started Dec 2024; status: active, not recruiting.
02
Drugs
03
Conditions
heart failure with preserved ejection fraction (HFpEF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07303556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07303556.